| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 5.522 | 169.588 | 301.752 | 343.597 | 264.377 | 522.731 |
| Total Income - EUR | - | - | - | - | 5.522 | 169.588 | 299.149 | 343.598 | 265.086 | 852.773 |
| Total Expenses - EUR | - | - | - | - | 6.628 | 143.515 | 269.548 | 355.825 | 298.794 | 686.008 |
| Gross Profit/Loss - EUR | - | - | - | - | -1.105 | 26.073 | 29.601 | -12.227 | -33.707 | 166.764 |
| Net Profit/Loss - EUR | - | - | - | - | -1.161 | 24.555 | 27.205 | -14.997 | -35.823 | 142.710 |
| Employees | - | - | - | - | 1 | 2 | 2 | 4 | 3 | 3 |
Check the financial reports for the company - Vitaplus Pharmalife S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 194.711 | 170.408 | 151.704 | 131.050 | 0 |
| Current Assets | - | - | - | - | 49.190 | 191.189 | 291.880 | 196.289 | 136.789 | 164.346 |
| Inventories | - | - | - | - | 44.794 | 136.087 | 210.083 | 113.359 | 83.997 | 0 |
| Receivables | - | - | - | - | 0 | 51.669 | 72.505 | 79.708 | 48.473 | 118.409 |
| Cash | - | - | - | - | 4.397 | 3.433 | 9.291 | 3.222 | 4.319 | 45.937 |
| Shareholders Funds | - | - | - | - | -1.119 | 23.468 | 50.152 | -14.936 | -50.713 | 92.280 |
| Social Capital | - | - | - | - | 42 | 52 | 51 | 51 | 51 | 50 |
| Debts | - | - | - | - | 50.309 | 362.432 | 412.136 | 364.021 | 327.007 | 72.066 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Vitaplus Pharmalife S.r.l.